1.245

0.40% -0.005

After Hours: 1.2207 -0.0243 -1.95%

Immunic Inc (IMUX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Immunic Inc stock is currently priced at $1.245, with a 24-hour trading volume of 1.41M. It has seen a -0.40% decreased in the last 24 hours and a +2.89% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.26 pivot point. If it approaches the $1.22 support level, significant changes may occur.

Previous Close:

$1.25

Open:

$1.23

24h Volume:

1.41M

Market Cap:

$112.15M

Revenue:

Net Income/Loss:

$-93.61M

P/E Ratio:

-0.363

EPS:

-3.43

Net Cash Flow:

$-71.16M

1W Performance:

-1.97%

1M Performance:

+2.89%

6M Performance:

+17.45%

1Y Performance:

-31.22%

1D Range:

$1.18

$1.26

52W Range:

$0.9451

$3.11

Immunic Inc Stock (IMUX) Company Profile

Name

Immunic Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

Address

11440 West Bernardo Court, Suite 300, San Diego

Employee

Twitter

@ImmunicInc

Next Earnings Date

2024-06-11

Latest SEC Filings

IMUX's Discussions on Twitter

Immunic Inc Stock (IMUX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-19-22	Resumed	H.C. Wainwright	Buy
Apr-15-21	Initiated	Aegis Capital	Buy
Mar-24-21	Initiated	JMP Securities	Mkt Outperform
Oct-02-20	Initiated	SVB Leerink	Outperform
Aug-26-20	Initiated	Piper Sandler	Overweight
Aug-07-20	Resumed	ROTH Capital	Buy
Jul-20-20	Initiated	BMO Capital Markets	Outperform
Jun-05-20	Initiated	Wedbush	Outperform
May-11-20	Initiated	H.C. Wainwright	Buy
Mar-25-20	Initiated	ROTH Capital	Buy
Jul-11-19	Initiated	Chardan Capital Markets	Buy

View All

Immunic Inc Stock (IMUX) Latest News

The Globe and Mail - The Globe and Mail

The Globe and Mail

Immunic chief medical officer discusses promising treatments to mark World IBD Day - Proactive Investors USA

Proactive Investors USA

Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day - Marketscreener.com

Marketscreener.com

Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day - Proactive Investors UK

Proactive Investors UK

Q4 2024 EPS Estimates for Immunic, Inc. (NASDAQ:IMUX) Lowered by Analyst - MarketBeat

MarketBeat

Earnings call: Immunic outlines progress and financials for Q1 2024 - Investing.com Australia

Investing.com Australia

Immunic Inc Stock (IMUX) Financials Data

Immunic Inc (IMUX) Net Income 2024

IMUX net income (TTM) was -$93.61 million for the quarter ending December 31, 2023, a +22.25% increase year-over-year.

Immunic Inc (IMUX) Cash Flow 2024

IMUX recorded a free cash flow (TTM) of -$71.16 million for the quarter ending December 31, 2023, a -9.05% decrease year-over-year.

Immunic Inc (IMUX) Earnings per Share 2024

IMUX earnings per share (TTM) was -$2.11 for the quarter ending December 31, 2023, a +44.03% growth year-over-year.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. The company is also developing IMU-935, an inverse agonist of RORyt; and IMU-856 for the restoration of the intestinal barrier function. Immunic, Inc. is headquartered in San Diego, California.